Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclopropyl-{4-[5-(3,4-dichlorophenyl)-2-[(1-methyl)-piperidin]-4-yl-3-propyl-3h-imidazol-4-yl]-pyrimidin-2-yl}amine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Cyclopropyl-{4-[5-(3,4-dichlorophenyl)-2-[ (1-methyl)piperidin ] - 4 - yl - 3 - prop yl - 3 h-imidazol – 4 – yl ] – pyrimidin – 2 – yl } amine is a synthetic small molecule belonging to the class of piperidinylimidazoles and aminopyrimidines. It acts as an inhibitor of c-Jun N-terminal kinase (JNK), a member of the mitogen activated protein kinase (MAPK) family involved in cellular stress signaling and apoptosis. This compound has been studied primarily as a chemical probe or experimental tool for JNK inhibition in biochemical and structural studies; it is not approved for clinical use or marketed as a pharmaceutical drug[1][2][8]. No clinical indications or therapeutic uses are established.
- Other names
- N-cyclopropyl-4-[4-(3,4-dichlorophenyl)-2-(1-methylpiperidin-4-yl)-1-propylimidazol-5-yl]pyrimidin-2-amineCyclopropyl-(4-(5-(3,4-Dichlorophenyl)-2-(1-Methyl-Piperidin)-4-Yl–3–Propyl–3h-Imidazol– 4-Yl)–Pyrimidin–2-Yl)Amine
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)
Beyond the preview
Go deeper on cyclopropyl-{4-[5-(3,4-dichlorophenyl)-2-[(1-methyl)-piperidin]-4-yl-3-propyl-3h-imidazol-4-yl]-pyrimidin-2-yl}amine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclopropyl-{4-[5-(3,4-dichlorophenyl)-2-[(1-methyl)-piperidin]-4-yl-3-propyl-3h-imidazol-4-yl]-pyrimidin-2-yl}amine.